SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (7645)11/4/1998 10:15:00 PM
From: Robert K.  Respond to of 17367
 
I concur with Jackie, and I also was hoping to the the the hospitals and docs will make the ethical decisons on patient care. Both your answers tend to reinforce that view. Insurance notwithstanding.
And also since the primary indications for neuprex are trauma, I agree that we wont wait for 8am monday to treat. Regarding surgery, it might be the low cost alternative anyway when you factor in complications from alternatives.
Note-lets not forget that a press release IS coming very soon. Probably within 5 days. What it contains is anyones guess.
All IMO.



To: Bluegreen who wrote (7645)11/4/1998 11:54:00 PM
From: jackie  Respond to of 17367
 
Didn't even talk to the insurance company until the whole episode was over, some eight weeks later. Insurance picked up every dime except for about $50 in routine drugs.

Insurance had no bearing on the treatments at all.

Jack


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News